Please assess the completion status of the following clinical trial:

Trial Title: 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has histologically proven squamous cell carcinoma of the head and neck which is biopsy accessible and is not considered curable by standard measures.~* Patient has a Karnofsky performance status \>/= 70%~* Patient has adequate bone marrow function: \*WBC \>/= 3,000 cells/mm\^3, \*ANC \>/= 1,500 cells/mm\^3, \*platelet count \>/= 100,000 cells/mm\^3, \*Hgb \>/= 9.0 g/dL.~* Patient has adequate liver function: \*total bilirubin level \</= 2.0 mg/dL, \*albumin \>/= 2.5 g/dL.~* Transaminases (SGOT and/or SGPT) may be up to 2.5 x ULN if alkaline phosphatase is \</= ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are \</= ULN.~* Patient has adequate renal function: a serum creatinine \< 2 mg/dl~* Patient has signed a written informed consent.~* Patient has received no more than 2 prior chemotherapeutic regimens for recurrent or metastatic disease. Prior biologic therapy is not included.~Exclusion Criteria:~* Patient has received 3 or more prior chemotherapeutic regimens for recurrent/metastatic disease.~* No biopsy accessible tissue.~* Patient has received radiation therapy within the past 6 months.~* Prior radiation to the biopsy site.~* Patient has signs or symptoms of acute infection requiring systemic therapy.~* Patient exhibits confusion, disorientation, or has a history of major psychiatric illness which may impair patient's understanding of the informed consent.~* Patient has grade 3 or 4 neurotoxicity from previous anticancer treatment or significant neuropathy from any cause.~* Patient requires total parenteral nutrition with lipids.~* Surgery is anticipated to leave patient unable to swallow the SCH66336 or 4-HPR daily.~* Patient has a history of uncontrolled heart disease (including arrhythmia, angina, congestive heart failure, or any heart condition that cannot be controlled with regular ongoing medication)~* Because of the known teratogenic effect of retinoids, pregnant women and women who are currently breast-feeding may not participate in this study. All women of childbearing potential must have a negative pregnancy test within 24 hours prior to enrolling in the study.~* Serious infection or other intercurrent illness requiring immediate therapy.~* Inability to swallow oral medications, or other medical or social factors interfering with compliance.~* Patients may not take high dose synthetic or natural Vitamin A derivatives (\>10,000 IU per day). Patients may not be taking high-dose vitamin A within 30 days of study entry.~* Patients should not take any anti-oxidants such as Vitamin E or Vitamin C~* Patients with pre-existing retinopathy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4-HPR + FTI (Type: EXPERIMENTAL): SCH66336 daily for 21 days each cycle and with 4-HPR daily on days 1-7 only. On day 1 of cycle 1, 4-HPR only beginning SCH66336 on day 2 of cycle 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).